The Changing Dynamics of Pharma Outsourcing in Asia

The dynamics of pharma outsourcing and location decisions in Asia are changing. Cost reduction is being augmented and will gradually be eclipsed by ‘footprint growth’ as a key factor shaping decisions. Companies need to set their strategic sights on a future world where Asia is not just a market and manufacturing powerhouse for the pharma industry, but could make a key contribution to drug discoveries as well.

In this publication, we examine the strategic forces that are shaping outsourcing and other location decisions in the region. We find that companies need to balance a number of factors, ranging from the forces that are affecting current and future pharmaceutical business models to the opportunities and constraints posed by the dynamics of growth, convergence and divergence at work in the Asia region. We look at how outsourcing in Asia is moving up the value chain, and at the expansion of clinical trials and manufacturing activity.

Click the following link to download the full article.